Transgene Biotek Limited announced that its statutory auditors, M/s Vasavi & Co., Chartered Accountants, resigned from their position with immediate effect on September 22, 2026.

The resignation was communicated to the BSE under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The audit firm cited pre-occupation with other assignments as the primary reason for stepping down, stating they were unable to devote sufficient time to the company's affairs.

Resignation details

The company filed an intimation with the BSE on September 23, 2026, confirming the cessation of the auditor's tenure. The firm, holding Firm Registration Number (FRN) 020965S, submitted a formal resignation letter to the Board of Directors on September 22, 2026. The letter was signed by Gollapudi Vasavi, Proprietor of M/s Vasavi & Co.

Next steps for appointment

Transgene Biotek stated it will take necessary steps to appoint a new statutory auditor in accordance with the applicable provisions of the Companies Act, 2013 and SEBI LODR Regulations. The company confirmed that no other material reasons for the resignation were disclosed by the auditor beyond the stated workload constraints.

The filing included a copy of the resignation letter received from the audit firm for regulatory records. The Managing Director, Koteswara Rao, signed the disclosure on behalf of the company.

Transgene Biotek Ltd has closed its trading window for dealing in securities effective October 1, 2026. This restriction applies to all Directors, Key Managerial Personnel (KMPs), Designated Employees, and Connected Persons as defined under the SEBI (Prohibition of Insider Trading) Regulations, 2015.

The trading window will remain closed until 48 hours after the declaration of the company's limited reviewed financial results for the second quarter ended September 30, 2026. This measure ensures compliance with insider trading norms during the sensitive period preceding the release of quarterly earnings.

Board meeting schedule

The company stated that the specific date of the Board Meeting for considering the un-audited financial results for the quarter ended September 30, 2026, will be intimated in due course. The filing was addressed to the Department of Corporate Services at BSE Limited on September 22, 2026.

Regulatory compliance details

The closure is mandated under the SEBI (Prohibition of Insider Trading) Regulations, 2015, read with subsequent amendments regarding trading restriction periods. The Managing Director, Dr K Koteswara Rao, signed the intimation letter to the stock exchange.